Major limits of A18 for clinical use in preventing NEC include the fact that while A18 is rapidly absorbed and approximately 97% bound in human plasma, it is extensively metabolized by CYP3A4 and CYP2C18, and plasma elimination half-life is only approximately 2 h in humans47, leaving much room for further improvement. The gene discussed is CYP2C18; the disease is necrotizing enterocolitis.